| Title |
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors
|
|---|---|
| Published in |
Clinical Pharmacology & Therapeutics, June 2015
|
| DOI | 10.1002/cpt.147 |
| Pubmed ID | |
| Authors |
J K Hicks, J R Bishop, K Sangkuhl, D J Müller, Y Ji, S G Leckband, J S Leeder, R L Graham, D L Chiulli, A LLerena, T C Skaar, S A Scott, J C Stingl, T E Klein, K E Caudle, A Gaedigk |
| Abstract |
Selective Serotonin Reuptake Inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org). This article is protected by copyright. All rights reserved. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 38% |
| Canada | 1 | 13% |
| Unknown | 4 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 50% |
| Scientists | 3 | 38% |
| Practitioners (doctors, other healthcare professionals) | 1 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 681 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | <1% |
| Unknown | 677 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 95 | 14% |
| Student > Master | 89 | 13% |
| Researcher | 81 | 12% |
| Student > Ph. D. Student | 69 | 10% |
| Student > Doctoral Student | 47 | 7% |
| Other | 131 | 19% |
| Unknown | 169 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 147 | 22% |
| Pharmacology, Toxicology and Pharmaceutical Science | 121 | 18% |
| Biochemistry, Genetics and Molecular Biology | 97 | 14% |
| Agricultural and Biological Sciences | 43 | 6% |
| Nursing and Health Professions | 18 | 3% |
| Other | 72 | 11% |
| Unknown | 183 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 30. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2023.
All research outputs
#1,348,001
of 26,017,215 outputs
Outputs from Clinical Pharmacology & Therapeutics
#173
of 4,619 outputs
Outputs of similar age
#16,171
of 281,374 outputs
Outputs of similar age from Clinical Pharmacology & Therapeutics
#1
of 28 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,619 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.0. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,374 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.